000124436 001__ 124436
000124436 005__ 20240228145514.0
000124436 0247_ $$2doi$$a10.15252/emmm.201607222
000124436 0247_ $$2pmid$$apmid:28373218
000124436 0247_ $$2pmc$$apmc:PMC5452049
000124436 0247_ $$2ISSN$$a1757-4676
000124436 0247_ $$2ISSN$$a1757-4684
000124436 0247_ $$2altmetric$$aaltmetric:18463621
000124436 037__ $$aDKFZ-2017-01313
000124436 041__ $$aeng
000124436 082__ $$a610
000124436 1001_ $$0P:(DE-He78)18e5b355e4a312d2065b1ae2a9d47654$$aMogler, Carolin$$b0$$eFirst author
000124436 245__ $$aHepatic stellate cells limit hepatocellular carcinoma progression through the orphan receptor endosialin.
000124436 260__ $$aWeinheim$$bWiley-VCH$$c2017
000124436 3367_ $$2DRIVER$$aarticle
000124436 3367_ $$2DataCite$$aOutput Types/Journal article
000124436 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1660827969_30652
000124436 3367_ $$2BibTeX$$aARTICLE
000124436 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000124436 3367_ $$00$$2EndNote$$aJournal Article
000124436 500__ $$aDKFZ-ZMBH Alliance
000124436 520__ $$aHepatocellular carcinoma (HCC) is among the most common and deadliest cancers worldwide. A major contributor to HCC progression is the cross talk between tumor cells and the surrounding stroma including activated hepatic stellate cells (HSC). Activation of HSC during liver damage leads to upregulation of the orphan receptor endosialin (CD248), which contributes to regulating the balance of liver regeneration and fibrosis. Based on the established role of endosialin in regulating HSC/hepatocyte cross talk, we hypothesized that HSC-expressed endosialin might similarly affect cell proliferation during hepatocarcinogenesis. Indeed, the histological analysis of human HCC samples revealed an inverse correlation between tumor cell proliferation and stromal endosialin expression. Correspondingly, global genetic inactivation of endosialin resulted in accelerated tumor growth in an inducible mouse HCC model. A candidate-based screen of tumor lysates and differential protein arrays of cultured HSC identified several established hepatotropic cytokines, including IGF2, RBP4, DKK1, and CCL5 as being negatively regulated by endosialin. Taken together, the experiments identify endosialin-expressing HSC as a negative regulator of HCC progression.
000124436 536__ $$0G:(DE-HGF)POF3-311$$a311 - Signalling pathways, cell and tumor biology (POF3-311)$$cPOF3-311$$fPOF III$$x0
000124436 588__ $$aDataset connected to CrossRef, PubMed,
000124436 7001_ $$0P:(DE-He78)5ef958977fa3c0658679b496419ce762$$aKönig, Courtney$$b1$$eFirst author
000124436 7001_ $$0P:(DE-He78)0792aae05ea250d2937cdfa6c9ca05fc$$aWieland, Matthias$$b2
000124436 7001_ $$0P:(DE-He78)cc84101e4a6f5a7a41c9012f423dbd0f$$aRunge, Anja$$b3
000124436 7001_ $$0P:(DE-He78)9be9200416a88a73cc9c25339b19b58f$$aBesemfelder, Eva$$b4
000124436 7001_ $$0P:(DE-He78)30816ab8532422ad8d4a8af55bc0d24b$$aKomljenovic, Dorde$$b5
000124436 7001_ $$aLongerich, Thomas$$b6
000124436 7001_ $$aSchirmacher, Peter$$b7
000124436 7001_ $$aAugustin, Hellmut G$$b8$$eLast author
000124436 773__ $$0PERI:(DE-600)2485479-7$$a10.15252/emmm.201607222$$gVol. 9, no. 6, p. 741 - 749$$n6$$p741 - 749$$tEMBO molecular medicine$$v9$$x1757-4684$$y2017
000124436 909CO $$ooai:inrepo02.dkfz.de:124436$$pVDB
000124436 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)18e5b355e4a312d2065b1ae2a9d47654$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000124436 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ef958977fa3c0658679b496419ce762$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000124436 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0792aae05ea250d2937cdfa6c9ca05fc$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000124436 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)cc84101e4a6f5a7a41c9012f423dbd0f$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000124436 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9be9200416a88a73cc9c25339b19b58f$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000124436 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)30816ab8532422ad8d4a8af55bc0d24b$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000124436 9131_ $$0G:(DE-HGF)POF3-311$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vSignalling pathways, cell and tumor biology$$x0
000124436 9141_ $$y2017
000124436 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000124436 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000124436 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000124436 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000124436 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000124436 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000124436 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEMBO MOL MED : 2015
000124436 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000124436 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000124436 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000124436 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000124436 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEMBO MOL MED : 2015
000124436 9201_ $$0I:(DE-He78)A190-20160331$$kA190$$lA190 Vaskuläre Onkologie und Metastasierung$$x0
000124436 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x1
000124436 9201_ $$0I:(DE-He78)E020-20160331$$kE020$$lE020 Med. Physik in der Radiologie$$x2
000124436 980__ $$ajournal
000124436 980__ $$aVDB
000124436 980__ $$aI:(DE-He78)A190-20160331
000124436 980__ $$aI:(DE-He78)L101-20160331
000124436 980__ $$aI:(DE-He78)E020-20160331
000124436 980__ $$aUNRESTRICTED